{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:50:56Z","timestamp":1776437456670,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10528-025-11130-2","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:51:39Z","timestamp":1747061499000},"page":"2082-2100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"64","author":[{"given":"Deema Hilmi","family":"Adawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Al-barghouthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia Ben","family":"Fredj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Lubada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dania Osama","family":"Njjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Ruzaygat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Aouam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"11130_CR1","doi-asserted-by":"publisher","DOI":"10.4172\/2325-9604.1000227","author":"D Adawi","year":"2023","unstructured":"Adawi D, Lubada M, Albarghouthi A, Slama A, Hallak H, Aouam K (2023) Develpment and clinical validation of an HPLC-PDA method of imatinib mesylate in human plasma: interest in therapeutic drug monitoring. J Pharm Drug Deliv Res. https:\/\/doi.org\/10.4172\/2325-9604.1000227","journal-title":"J Pharm Drug Deliv Res"},{"issue":"9","key":"11130_CR2","doi-asserted-by":"publisher","first-page":"e23374","DOI":"10.1002\/jcla.23374","volume":"34","author":"M Ammar","year":"2020","unstructured":"Ammar M, Louati N, Frikha I, Medhaffar M, Ghozzi H, Elloumi M et al (2020) Overexpression of P-glycoprotein and resistance to imatinib in chronic myeloid leukemia patients. J Clin Lab Anal 34(9):e23374","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"11130_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2125.2012.04343.x","volume":"75","author":"CL Aquilante","year":"2013","unstructured":"Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP et al (2013) Impact of the CYP2C8* 3 polymorphism on the drug\u2013drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 75(1):217\u2013226","journal-title":"Br J Clin Pharmacol"},{"issue":"S10","key":"11130_CR4","doi-asserted-by":"publisher","first-page":"S1541","DOI":"10.21037\/tcr.2017.09.08","volume":"6","author":"DT Barratt","year":"2017","unstructured":"Barratt DT, Somogyi AA (2017) Role of pharmacogenetics in personalised imatinib dosing. Transl Cancer Res 6(S10):S1541\u2013S1557","journal-title":"Transl Cancer Res"},{"key":"11130_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40262-016-0494-0","volume":"56","author":"DT Barratt","year":"2017","unstructured":"Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA (2017) CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clin Pharmacokinet 56:977\u2013985","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"11130_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/fcp.12007","volume":"27","author":"S Bouchet","year":"2013","unstructured":"Bouchet S, Titier K, Moore N, Lassalle R, Ambrosino B, Poulette S et al (2013) Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol 27(6):690\u2013697","journal-title":"Fundam Clin Pharmacol"},{"key":"11130_CR7","doi-asserted-by":"publisher","first-page":"10564","DOI":"10.1200\/jco.2008.26.15_suppl.10564","volume":"26","author":"B Bui","year":"2008","unstructured":"Bui B, Italiano A, Miranova A, Bouchet S, Molimard M (2008) Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses. J Clin Oncol 26:10564","journal-title":"J Clin Oncol"},{"issue":"22","key":"11130_CR8","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/cncr.34478","volume":"128","author":"F Cheng","year":"2022","unstructured":"Cheng F, Zeng F, Li Q, Cui Z, Chen Y, Li W, Zhang Y (2022) Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia. Cancer 128(22):3951\u20133958","journal-title":"Cancer"},{"issue":"11","key":"11130_CR9","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1002\/cncr.20292","volume":"100","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Quintas A, Giles F, Shan J, Rios MB et al (2004) Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer: Interdiscip Int J Am Cancer Soc 100(11):2396\u20132402","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"issue":"3","key":"11130_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/bcp.15551","volume":"89","author":"C Dalle Fratte","year":"2023","unstructured":"Dalle Fratte C, Gagno S, Roncato R, Polesel J, Zanchetta M, Buzzo M et al (2023) CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients. Br J Clin Pharmacol 89(3):1089\u20131098","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"11130_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, O\u2019brien SG, Ford JM, Druker BJ (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21(8):1637\u20131647","journal-title":"J Clin Oncol"},{"issue":"20","key":"11130_CR12","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","volume":"12","author":"C Delbaldo","year":"2006","unstructured":"Delbaldo C, Chatelut E, R\u00e9 M, Deroussent A, S\u00e9ronie-Vivien S, Jambu A et al (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12(20):6073\u20136078","journal-title":"Clin Cancer Res"},{"issue":"1","key":"11130_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1124\/dmd.112.048017","volume":"41","author":"AM Filppula","year":"2013","unstructured":"Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT (2013) Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos 41(1):50\u201359","journal-title":"Drug Metab Dispos"},{"key":"11130_CR14","first-page":"895","volume":"24","author":"S Gagno","year":"2023","unstructured":"Gagno S, Fratte CD, Posocco B, Buonadonna A, Fumagalli A, Guardascione M et al (2023) Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation. Future Med 24:895\u2013900","journal-title":"Future Med"},{"issue":"21","key":"11130_CR15","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1182\/blood.V120.21.3788.3788","volume":"120","author":"V Gota","year":"2012","unstructured":"Gota V, Sharma A, Paradkar A, Patil A, Khattry N, Menon H et al (2012) Association between CYP3A4 polymorphisms, trough imatinib plasma concentration and cytogenetic response in chronic phase chronic myeloid leukemia (CML-CP). Blood 120(21):3788","journal-title":"Blood"},{"issue":"3","key":"11130_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","volume":"9","author":"F Guilhot","year":"2004","unstructured":"Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. Oncologist 9(3):271\u2013281","journal-title":"Oncologist"},{"issue":"5","key":"11130_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3324\/haematol.2011.045666","volume":"97","author":"F Guilhot","year":"2012","unstructured":"Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I et al (2012) Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica 97(5):731","journal-title":"Haematologica"},{"issue":"10","key":"11130_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927","journal-title":"N Engl J Med"},{"issue":"7","key":"11130_CR19","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3324\/haematol.2020.247767","volume":"106","author":"L Janssen","year":"2021","unstructured":"Janssen L, Blijlevens NM, Drissen MM, Bakker EA, Nuijten MA, Janssen JJ et al (2021) Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica 106(7):1876","journal-title":"Haematologica"},{"issue":"6","key":"11130_CR20","first-page":"1495","volume":"73","author":"M Kaza","year":"2016","unstructured":"Kaza M, Piorkowska E, Filist M, Rudzki PJ (2016) HPLC-UV ASSAY OF IMATINIB IN HUMAN PLASMA OPTIMIZED FOR BIOEQUIVALENCE STUDIES. Acta Pol Pharm 73(6):1495\u20131503","journal-title":"Acta Pol Pharm"},{"issue":"8","key":"11130_CR21","first-page":"4022","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood J Am Soc Hematol 111(8):4022\u20134028","journal-title":"Blood J Am Soc Hematol"},{"issue":"8","key":"11130_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/aps.2010.79","volume":"31","author":"Q-b Li","year":"2010","unstructured":"Li Q-b, Chen C, Chen Z-c, Wang H-x, Wu Y-l, You Y, Zou P (2010) Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacol Sin 31(8):999\u20131004","journal-title":"Acta Pharmacol Sin"},{"key":"11130_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40487-016-0035-x","volume":"4","author":"N Maddin","year":"2016","unstructured":"Maddin N, Husin A, Gan SH, Aziz BA, Ankathil R (2016) Impact of CYP3A4* 18 and CYP3A5* 3 polymorphisms on imatinib mesylate response among chronic myeloid leukemia patients in Malaysia. Oncol Ther 4:303\u2013314","journal-title":"Oncol Ther"},{"issue":"3","key":"11130_CR24","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.4238\/2013.July.8.7","volume":"12","author":"S Minhas","year":"2013","unstructured":"Minhas S, Setia N, Pandita S, Saxena R, Verma I, Aggarwal S (2013) Prevalence of CYP2C8 polymorphisms in a North Indian population. Genet Mol Res 12(3):2260\u20132266","journal-title":"Genet Mol Res"},{"issue":"5","key":"11130_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38(5):645\u2013654","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"11130_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","volume":"161","author":"N Nebot","year":"2010","unstructured":"Nebot N, Crettol S, d\u2019Esposito F, Tattam B, Hibbs DE, Murray M (2010) Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161(5):1059\u20131069","journal-title":"Br J Pharmacol"},{"issue":"7","key":"11130_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40261-020-00921-7","volume":"40","author":"M\u00c1 Pena","year":"2020","unstructured":"Pena M\u00c1, Muriel J, Saiz-Rodr\u00edguez M, Borobia AM, Abad-Santos F, Fr\u00edas J, Peir\u00f3 AM (2020) Effect of cytochrome P450 and ABCB1 polymorphisms on imatinib pharmacokinetics after single-dose administration to healthy subjects. Clin Drug Investig 40(7):617\u2013628","journal-title":"Clin Drug Investig"},{"key":"11130_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5455\/medscience.2019.08.9189","volume":"9","author":"ZU Sahinogullari","year":"2020","unstructured":"Sahinogullari ZU (2020) Genetic polymorphism of CYP2C8* 4 in a healthy Turkish population. Med Sci Int Med J 9:314\u2013319","journal-title":"Med Sci Int Med J"},{"issue":"4","key":"11130_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/biomedicines8040094","volume":"8","author":"M Saiz-Rodr\u00edguez","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Almenara S, Navares-G\u00f3mez M, Ochoa D, Rom\u00e1n M, Zubiaur P et al (2020) Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines 8(4):94","journal-title":"Biomedicines"},{"issue":"5\u20136","key":"11130_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000324900","volume":"87","author":"N Takahashi","year":"2011","unstructured":"Takahashi N, Miura M (2011) Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology 87(5\u20136):241\u2013248","journal-title":"Pharmacology"},{"issue":"11","key":"11130_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H et al (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55(11):731\u2013737","journal-title":"J Hum Genet"},{"issue":"5","key":"11130_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10147-023-02325-x","volume":"28","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Takahashi T, Nishida T, Kurokawa Y, Nakajima K, Koh M et al (2023) Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST. Int J Clin Oncol 28(5):680\u2013687","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"11130_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40262-023-01260-4","volume":"62","author":"RA van Eerden","year":"2023","unstructured":"van Eerden RA, IJzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NA, Visser AM et al (2023) CYP3A4* 22 genotype-guided dosing of kinase inhibitors in cancer patients. Clin Pharmacokinet 62(8):1129\u20131139","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"11130_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/FPC.0000000000000278","volume":"27","author":"MC Verboom","year":"2017","unstructured":"Verboom MC, Visser L, Kouwen S, Swen JJ, Diepstraten J, Posthuma WF et al (2017) Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenet Genom 27(6):223\u2013226","journal-title":"Pharmacogenet Genom"},{"issue":"4","key":"11130_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","volume":"37","author":"M von Mehren","year":"2011","unstructured":"von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291\u2013299","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"11130_CR36","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","volume":"98","author":"N Widmer","year":"2008","unstructured":"Widmer N, Decosterd L, Leyvraz S, Duchosal M, Rosselet A, Debiec-Rychter M et al (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98(10):1633\u20131640","journal-title":"Br J Cancer"},{"key":"11130_CR37","doi-asserted-by":"publisher","first-page":"1115141","DOI":"10.3389\/fsurg.2023.1115141","volume":"10","author":"X Wu","year":"2023","unstructured":"Wu X, Ge Y, He X, Li J, Zhang J (2023) Changes in imatinib plasma trough level during long-term treatment in patients with intermediate-or high-risk gastrointestinal stromal tumors: relationship between covariates and imatinib plasma trough level. Front Surg 10:1115141","journal-title":"Front Surg"},{"issue":"Suppl 9","key":"11130_CR38","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/cncr.32751","volume":"126","author":"Y Xia","year":"2020","unstructured":"Xia Y, Chen S, Luo M, Wu J, Cai S, He Y et al (2020) Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. Cancer 126(Suppl 9):2054\u20132061","journal-title":"Cancer"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-025-11130-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10528-025-11130-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-025-11130-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:02:59Z","timestamp":1776434579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10528-025-11130-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["11130"],"URL":"https:\/\/doi.org\/10.1007\/s10528-025-11130-2","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}